Results 151 to 160 of about 131,629 (255)

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Thirty-Nine Years Later: A Case Report and Literature Review of Delayed Pleural and Pericardial Effusions After Chest Radiotherapy for Non-Hodgkin Lymphoma. [PDF]

Cureus
Wagle L, Timshina A, Pant HN, Pathak V.
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

A Rare Case of Non-Hodgkin B-Cell Lymphoma Following Invasive Lobular Carcinoma of the Breast: A Case Report. [PDF]

Curr Oncol
Bertulla E, Diaz R, Mascherini M, Casaccia M, Depaoli F, Cuniolo L, Cornacchia C, Margarino C, Murelli F, Franchelli S, Pesce M, Boccardo C, Gipponi M, De Cian F, Fregatti P.   +14 more
europepmc   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

Prognostic factors and relapse in nodal vs. extranodal non-Hodgkin lymphoma of the ENT region: a prospective cohort study. [PDF]

J Med Life
Morar R, Varga NI, Balasa Virzob CR, Balica NC, Horhat ID, Chioreanu A, Sarau OS, Tanasescu S, Susan R, Mot IC.   +9 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

B-Cell Lymphoma Diagnosed in an Explanted Liver of a Patient With Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis. [PDF]

ACG Case Rep J
Kaufman L, Chi H, Bushrow L, Yearsley M, Mumtaz K.   +4 more
europepmc   +1 more source

Organoids in Haematologic Research: Advances and Future Directions

Cell Proliferation, EarlyView.
This review focuses on the advancements in organoid technology and its transformative role in haematological research, particularly in the modelling of haematopoietic tissues, blood diseases and drug development. It also offers an outlook on the future prospects of organoids in personalised medicine and the study of disease mechanisms.
Liangzheng Chang, Lu Li, Yuling Han, Hui Cheng, Liuliu Yang   +4 more
wiley   +1 more source

A Rare Case of Non-Hodgkin Lymphoma Presenting as a Penile Mass [PDF]

Turk J Haematol
Sevinç AH, Teke İ, Hürdoğan Ö, Altay A, Cantürk Z, Dursun M, Kadıoğlu A.   +6 more
europepmc   +1 more source